Favipiravir COVID-19 treatment drug

COVID-19 treatment drug launched by Indoco Remedies – Favipiravir

Indoco Remedies – the drug manufacturer declared the launch of Fevindo (Favipiravir) 400 mg tablets in India on 26 September 2020.

The firm is a fully incorporated, research-oriented pharma company with a presence in 55 nations. It is a Mumbai-based pharma company engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients and Formulations.

This drug is an antiviral medicine used against the RNA‐based influenza virus. The medication has actually been authorized by the Drugs Controller General of India for the treatment against SARS-CoV-2. The firm stated in the declaration that this medication minimizes pill burden by half as well as makes sure hassle-free dosing and better patient conformity.

This drug will certainly be provided at all government accepted COVID-19 care centers as well as chosen physicians throughout the nation. The firm has started dedicated helplines to make sure increased access to Fevindo 400 throughout the country.

In the COVID-19 treatment array, Indoco Remedies has 2 more new products for launch along with Fevindo 400, these include Immunity booster chewable tablets with Vitamin D, Vitamin C, and Zinc, and Povidone Iodine Gargle.

According to the information from the Ministry of Health

and Family Welfare, Government of India, as of today, the total COVID-19 confirmed cases around the world are 3,30,78,537 with 9,97,737 fatalities. India has reported 60,74,702 positive cases and 95,542 fatalities while 48,49,584 patients have recovered.

On 25 September 2020, the shares of Indoco Remedies was closed 2.51% higher at Rs 261.1, notably in the past 1 month, the stock has acquired 7% compared to a 0.83% surge in the Nifty Pharma index. The firm’s combined total profit surged 821.10% to Rs 17.04 crore on a 7.9% rise in total sales to Rs 266.80 crore in Q1 June 2020 over Q1 June last year.

After the pharmaceutical firm declared the launch of Fevindo 400 mg tablets in India, the shares of Indoco Remedies rose 9% to Rs 284 on the BSE on Monday.

Source

COVID-19 treatment drug launched by Indoco Remedies – Favipiravir

Author: Sruthi S

LEAVE A REPLY

Please enter your comment!
Please enter your name here